{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 460025906
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = Fab'
| source = zu/o
| target = [[TNF alpha]]
<!-- Clinical data -->
| tradename = Cimzia
| Drugs.com = {{drugs.com|CDI|certolizumab_pegol}}
| MedlinePlus = a608041
| pregnancy_AU = 
| pregnancy_US = B
| pregnancy_category = 
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = Rx-only
| legal_status = 
| routes_of_administration = Subcutaneous
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = about 11 days
| excretion = [[Renal]] ([[Macrogol|PEG]] only)
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 428863-50-7
| ATC_prefix = L04
| ATC_suffix = AB05
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = UMD07X179E
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03441
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201831
<!-- Chemical data -->
| C=2115 | H=3252 | N=556 | O=673 | S=16
| molecular_weight = 47,750 g/mol
}}

'''Certolizumab pegol''' (CDP870, tradename '''Cimzia''') is a biologic medication for the treatment of [[Crohn's disease]],<ref name="pmid17634458">{{cite journal |vauthors=Sandborn WJ, Feagan BG, Stoinov S |title=Certolizumab pegol for the treatment of Crohn's disease |journal=N. Engl. J. Med. |volume=357 |issue=3 |pages=228–38 |date=July 2007 |pmid=17634458 |doi=10.1056/NEJMoa067594|display-authors=etal}}</ref><ref>{{cite journal|last=Goel|first=Niti|author2=Sue Stephens|title=Certolizumab pegol|journal=MAbs|year=2010|volume=2|issue=2|pages=137–147|doi=10.4161/mabs.2.2.11271|url=http://www.landesbioscience.com/journals/17/article/11271/|pmid=20190560|pmc=2840232}}</ref> [[rheumatoid arthritis]], [[psoriatic arthritis]] and [[ankylosing spondylitis]]. It is a fragment of a [[monoclonal antibody]] specific to [[tumor necrosis factor alpha]] (TNF-α) and is manufactured by [[UCB (company)|UCB]].<ref name="pmid15934837">{{cite journal |vauthors=Kaushik VV, Moots RJ |title=CDP-870 (certolizumab) in rheumatoid arthritis |journal=Expert opinion on biological therapy |volume=5 |issue=4 |pages=601–6 |date=April 2005 |pmid=15934837 |doi=10.1517/14712598.5.4.601}}</ref><ref name="Cimzia Label and Approval History">{{cite web | url = http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA index.cfm?fuseaction=Search.Label_ApprovalHistory | title = Cimzia Label and Approval History | work = Drugs@FDA | publisher = [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) | accessdate = 2009-11-15 }}</ref><ref>{{cite web|url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125160s241lbl.pdf|title=Cimzia Prescribing Information|last=|first=|date=April 2016|website=|publisher=US Food and Drug Administration (FDA)|format=PDF|access-date=2016-08-21}}</ref>

==Medical uses==

;Crohn's Disease: On April 22, 2008, the [[Food and Drug Administration (United States)|U.S. FDA]] approved Cimzia for the treatment of Crohn's disease in people who did not respond sufficiently or adequately to standard therapy.<ref name="Cimzia Label and Approval History"/><ref>[http://www.ucb.com/media-room/newsdetail/?det=1314787 UCB press release - Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease]. Retrieved April 22, 2008.</ref><ref>{{cite web | url = http://www.medscape.com/viewarticle/573833 | title = FDA Approvals: Patanase, Actonel, Cimzia | last = Waknine | first = Yael | date = May 1, 2008 | publisher = [[Medscape]] | accessdate = 2008-05-01}}</ref>

;Rheumatoid arthritis: On June 26, 2009, the [[Committee for Medicinal Products for Human Use]] (CHMP) of the [[European Medicines Agency]] (EMA) issued a positive opinion recommending that the European Commission grant a marketing authorisation for Cimzia for the treatment of rheumatoid arthritis only - the CHMP refused approval for the treatment of Crohn's disease. The marketing authorisation was granted to UCB Pharma SA on October 1, 2009.<ref>{{cite web | url=http://www.emea.europa.eu/humandocs/Humans/EPAR/cimzia/cimzia.htm | title= Cimzia European Public Assessment Report | publisher=[[European Medicines Agency]] | accessdate=November 15, 2009 }}</ref>

;Psoriatic arthritis: On September 27, 2013, the [[Food and Drug Administration (United States)|U.S. FDA]] approved Cimzia for the treatment of adult patients with active [[psoriatic arthritis]].<ref>{{cite web | url=http://www.ucb.presscentre.com/News/Cimzia-certolizumab-pegol-approved-by-the-U-S-FDA-for-treatment-of-adult-patients-with-active-ps-45c.aspx | title=Cimzia (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis | accessdate=October 1, 2013 | deadurl=yes | archiveurl=https://archive.is/20131001130038/http://www.ucb.presscentre.com/News/Cimzia-certolizumab-pegol-approved-by-the-U-S-FDA-for-treatment-of-adult-patients-with-active-ps-45c.aspx | archivedate=October 1, 2013 | df= }}</ref>

== Method of action ==

Certolizumab pegol is a monoclonal antibody directed against [[tumor necrosis factor alpha]]. More precisely, it is a [[PEGylated]] [[Fab']] fragment of a humanized [[TNF inhibitor]] monoclonal antibody.<ref name="Schreiber" />

==Clinical trials==

;Crohn's disease: Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol versus [[placebo]] in moderate to severe active Crohn's disease.<ref name="pmid17634458" /><ref name="Schreiber">Schreiber S. et al., Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase 3 study (precise), Gut, 2005, 54, suppl7, A82</ref><ref>Sandborn et al., Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled Phase 3 study (PRECiSE 1), Gastroenterology, 2006, 130, A107</ref><ref>{{cite press release| url = http://ir.ucb-group.com/phoenix.zhtml?c=137495&p=irol-newsArticle&ID=919693| title = New Analysis Shows Cimzia (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn’s Disease| date = October 23, 2006| publisher = UCB| accessdate = 2009-11-15}}</ref>

;Axial spondyloarthritis: In 2013, a phase 3 double blind randomized placebo-controlled study found significantly positive results in patient self-reported questionnaires, with rapid improvement of function and pain reduction, in patients with [[axial spondyloarthritis]].<ref>{{cite journal|vauthors=Sieper J, Tubergen A, Coteur G, Woltering F, Landewe R | url = https://www.sciencedirect.com/science/article/pii/S1098301513012217?np=y| title=PMS50 – Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study| date = May 2013| journal = Value in Health| volume = 16| issue = 3| pages = A227| accessdate = 2013-05-18| doi = 10.1016/j.jval.2013.03.1150}}</ref>

;Rheumatoid arthritis: Certolizumab appears beneficial in those with [[rheumatoid arthritis]].<ref name=Cochrane2014>{{cite journal|last1=Ruiz Garcia|first1=V|last2=Jobanputra|first2=P|last3=Burls|first3=A|last4=Cabello|first4=JB|last5=Vela Casasempere|first5=P|last6=Bort-Marti|first6=S|last7=Kynaston-Pearson|first7=FJ|title=Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.|journal=The Cochrane database of systematic reviews|date=Sep 18, 2014|volume=9|pages=CD007649|pmid=25231904|doi=10.1002/14651858.CD007649.pub3}}</ref>

== Side effects ==

Significant side effects occur in 2% of people who take the medication.<ref name=Cochrane2014/>

== References ==

{{reflist|2}}

== External links ==

* {{MeshName|certolizumab+pegol}}
* [http://www.cimzia.com Cimzia Website]

{{Immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Biotechnology]]
[[Category:TNF inhibitors]]
[[Category:Immunosuppressants]]
[[Category:Belgian inventions]]